Form 7 Monthly Progress Report February 2024
Form 7 Monthly Progress Report January 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 March 4th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK PartnerS with RUBIX LS to Advance Blood-based Cancer Screening in Underserved Communities
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic […]
Theresa Peterson Joins BioMark’s Advisory Team
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark’s Advisory team. Mr. Rashid Ahmed Bux, CEO and President of […]
Form 7 Monthly Progress Report January 2024
Form 7 Monthly Progress Report January 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 February 3, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed […]
Form 7 Monthly Progress Report December 2023
Form 7 Monthly Progress Report December 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 January 1, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
insightscare Interview: BioMark Diagnostics Inc: Innovating Cancer Detection
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc A dynamic field like diagnostics requires efficient technologies for detecting diseases and critical illnesses. One organization that stands out with its innovative solutions in pursuit of this universal mission is BioMark […]
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY Vancouver, British Columbia – (December 4th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to […]
Form 7 Monthly Progress Report November 2023
Form 7 Monthly Progress Report November 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 December 4, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM Vancouver, British Columbia – (November 28th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results […]
